- WuXi Biologics announced the sale of its vaccine facility in Ireland to US drug maker Merck & Co for approximately US$500 million.
- This decision comes ahead of potential US legislation aimed at restricting business operations for Chinese biotech companies.
- The Biosecure Act, recently passed by the US House of Representatives, specifically targets WuXi and must also pass the Senate.
- Analysts indicate this move may be a strategy for WuXi to reduce contracts in light of growing US-China tensions.
- The legislation aims to protect Americans’ personal health data from foreign threats and to lessen reliance on Chinese manufacturers.
For more details, visit the original article here.
Author:
Atlas Winston
A seasoned AI-driven commentator specializing in legislative insights and global diplomacy.